🔥 Featured Questions
🔥 Trending:🆕 NewestEntertainmentBeauty & SkincareRelationshipsFood & DrinkBooks
🗂️ Categories:EntertainmentBooksBeauty & SkincareFood & DrinkTech & AIRelationshipsLifestyle & TrendsMoney & FinanceSports
Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?

On August 19, 2026, Moderna's shares skyrocketed as much as 177% in a single session -- the biggest one-day gain in the company's history -- after it and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, hit its primary and secondary endpoints in combination with Keytruda in a Phase 3 melanoma trial of over 1,100 patients. The move added roughly $44 billion in market value in hours and instantly vaulted Moderna past every Wall Street analyst's price target, since the stock had carried only a consensus "Hold" rating and a $52.95 average target just the day before. Short sellers, caught badly offside, are estimated to have lost around $5.5 billion in the squeeze. Is this a legitimate re-rating of a real oncology breakthrough, an overexcited bet on a speculative pipeline still years from approval, or a technically-driven overreaction fueled by short covering that could partially unwind?

🗳️ 14 votes so far🏆 Leading: It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight. (36%)🥈 It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype. (36%)🥉 It's an overreaction -- a short-squeeze, not a rational re-rating. Even after nearly tripling, Moderna's stock remains roughly 67% below its August 2021 peak, and its core COVID vaccine business had been shrinking for years -- one successful trial doesn't erase that structural decline overnight. Trading volume spiked to about 1,819% above average and short sellers reportedly lost $5.5 billion in the move, hallmarks of a technically-driven squeeze where forced short covering, not careful valuation, drove the size and speed of the spike. (29%)⚖️ Split decision🌍 🇨🇳 China, 🇦🇴 Angola
It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight.
It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype.
It's an overreaction -- a short-squeeze, not a rational re-rating. Even after nearly tripling, Moderna's stock remains roughly 67% below its August 2021 peak, and its core COVID vaccine business had been shrinking for years -- one successful trial doesn't erase that structural decline overnight. Trading volume spiked to about 1,819% above average and short sellers reportedly lost $5.5 billion in the move, hallmarks of a technically-driven squeeze where forced short covering, not careful valuation, drove the size and speed of the spike.

Poll as Guest Infographics
Also worth a voteModerna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?48% of Americans hope AI cures cancer or Alzheimer's — but only 15% trust the companies building it. Is that optimism justified?
From around the web

Similar to hewsay's "Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?"

Quoted & linked with attribution — not a hewsay user post.
# AI is curing cancer (Moderna's Intismeran vaccine). It doesn't seem like the connection between AI and Moderna and Merck's breakthrough with its skin cancer vaccine, Intismeran, has been made. Moderna stock (MRNA) has gone up 83% year to date on the news that the vaccine is ...
reddit.com · Reddit
View original
# I Just Bought $510K Worth of Moderna Stock. r/ModernaStock - I Just Bought $510K Worth of Moderna Stock. Moderna (MRNA) is completely undervalued right now. It's clear that short sellers are driving down the price in the short term, but in the mid-to-long term, I believe the...
reddit.com · Reddit
View original
Which LLM would you use? 1

Like chatGPT or..

🏆 Leading: chatGPT (75%)🥈 Gemini (25%)🌍 🇨🇳 China, 🇪🇬 Egypt

Poll as Guest Infographics
Also worth a voteWhich AI tool do you actually reach for the most?Which AI coding tool is actually earning a spot in your daily workflow?The gen AI I use everyday
From around the web

Similar to hewsay's "Which LLM would you use?"

Quoted & linked with attribution — not a hewsay user post.
whichever LLM you are most comfortable with is the brain and an extension of you and your thinking. Find one that you feel does deep research
reddit.com · Reddit
View original
Claude is excellent for long-form analysis and nuanced writing. Gemini has improved a lot and is great if you're deep in the Google ecosystem.
reddit.com · Reddit
View original